检索结果-南通市图书馆

Cancer Innovation 2022年第1期1卷 3-24页

作者： Professional Committee on Clinical Research of oncology Drugs,Chinese Anti‐Cancer Association Expert Committee for Monitoring the Clinical Application of Antitumor Drugs Breast Cancer Expert Committee of National Cancer Quality Control Center| Cancer Chemotherapy Quality Control Expert Committee of Beijing Cancer Treatment Quality Control and Improvement Center Fei Ma Binghe Xu 不详 department of Medical oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China departmentofMedical oncology andClinicalTrialCenter National CancerCenter/NationalClinical Research CenterforCancer/Cancer HospitalChineseAcademyofMedical Sciences andPekingUnionMedical CollegeBeijing100021China

Antibody‐drug conjugates(ADCs)are targeted biological agents composed of a cytotoxic drug linked to a monoclonal antibody through a *** monoclonal antibody targets tumor cells and transports small‐molecule cytotoxic drugs for specific delivery and minimal off‐target side *** is necessary for clinicians to understand the molecular characteristics and mechanisms of ***'survival mainly depends on the appropriate dose and course of treatment and also on proper management of adverse *** consensus provides a systematic review of commercially available ADCs and further discusses the clinical application and management of ADCs.

关键词： malignant tumors antibody‐drug conjugates monoclonal antibodies cytotoxic drugs safety management

CACA guidelines for holistic integrative management of rectal cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Holistic Integrative oncology 2023年第1期2卷 1-31页

作者： Committee of Colorectal Cancer Society Chinese Anti-Cancer Association Guiyu Wang Daiming Fan Jin Gu Kefeng Ding Xuedong Fang Lin Shen Zhongfa Xu Jianmin Xu Jianchun Cai Lianming Cai Sanjun Cai Gong Chen Jiansi Chen Longwei Cheng Yong Cheng Pan Chi Binbin Cui Guanghai Dai Chuangang Fu Yanhong Gu Guodong He Junhong Hu Jing Huang Rui Huang Zhongcheng Huang Zheng Jiang Zhigang Jie Haixing Ju Hai Li Jian Li Jun Li Ming Li Yaoping Li Yunfeng Li Guole Lin Haiying Liu Ming Liu Qian Liu Zhizhong Pan Yifan Peng Niansong Qian Meng Qiu Li Ren Yueming Sun Jianqiang Tang Qingchao Tang Yuan Tang Kaixiong Tao Min Tao Haijiang Wang Meng Wang Zejun Wang Zhengguang Wang Ziqiang Wang Ziwei Wang Shaozhong Wei Baocai Xing Bin Xiong Ye Xu Su Yan Bin Yang Chunkang Yang Qinghua Yao Yingjiang Ye Ying Yuan Guozhi Zhang Haizeng Zhang Hongmei Zhang Zhen Zhang Yunshi Zhong Ji Zhu Yuan Zhu Yuping Zhu Shuangmei Zou Yuliuming Wang Jingfang Lv Enrui Liu Ming Yang Qian Zhang Weiyuan Zhang Lin Zhang Jun Luo Zhaoxu Zheng Zhixun Zhao Zheng Liu Jinhua Tao Haiyang Huang Tianli Chen Xishan Wang 不详 department of Colorectal Cancer Surgery The Second Affiliated Hospital of Harbin Medical UniversityHarbinChina State key Laboratory of Cancer Biology National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive DiseasesFourth Military Medical UniversityXi’anChina department of Gastrointestinal SurgeryⅢ Peking University Cancer HospitalBeijingChina department of Gastrointestinal Surgery Peking University Shougang HospitalBeijingChina department of Colorectal Surgery and oncology(Key Laboratory of Cancer Prevention and Intervention China National Ministry of EducationKey Laboratory of Molecular Biology in Medical SciencesZhejiang Provincial Clinical Research Center for CANCER)The Second Affiliated HospitalZhejiang University School of MedicineHangzhouZhejiangChina department of Gastrointestinal and Colorectal Surgery The China-Japan Union Hospital of Jilin University(The Third Hospital of Jilin University)ChangchunChina department of Gastrointestinal oncology Key laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing)Peking University Cancer Hospital&InstituteBeijingChina Gastrointestinal department of The Third Affiliated hospital of Shandong First Medical university TaianShandongChina department of Colorectal Surgery Zhongshan Hospital Fudan UniversityShanghaiChina Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology ShanghaiChina Zhongshan hospital Xiamen university XiamenChina department of Abdominal oncology Surgery Ganzhou Cancer HospitalGanzhouJiangxiChina Fudan university Shanghai Cancer Center ShanghaiChina department of colorectal surgery Sun Yat-sen University Cancer CenterGuangzhouChina Guangxi Medical university Cancer hospital NanningChina jilin Cancer hospital ChangchunChina department of Gastrointestinal Surgery the First Affiliated Hospital of Chongqing Medical UniversityChongqingChina department of Colorectal Surgery Fujian Medical University Union HospitalFuzhou

Purpose Colorectal cancer is a common malignant tumor *** china,the ratio of rectal cancer to coloncancer in terms of incidence is close to 1:*** rectal cancer accounts for more than half of all cases of rectal *** recent years,the proportion of rectal cancer has trended downward,however the incidence of rectal cancer inyounger adults is *** CACA Guidelines for Holistic Integrative Management of Rectal Cancer were editedto help improve the diagnosis and comprehensive treatment in *** This guideline has been prepared by consensuses reached by the CACA Committee of Colorectal CancerSociety,based on a careful review of the latest evidence including china’s studies,and referred to domestic and internationalrelative guidelines,also considered china’s specific national conditions and clinical *** The CACA Guidelines for Holistic Integrative Management of Rectal Cancer include the epidemiology of rectalcancer,prevention and screening,diagnosis,treatment of nonmetastatic and metastatic rectal cancer,follow-up,and whole-course rehabilitation *** Committee of Colorectal Cancer Society,Chinese Anti-Cancer Association,standardizes the diagnosisand treatment of rectal cancer in china through the formulation of the CACA Guidelines.

关键词： Rectal cancer Guideline Screening Diagnosis Treatment Rehabilitation management Holistic integrative medicine

Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2017年第1期2卷 242-250页

作者： Daniel A Luedtke Xiaojia Niu Yihang Pan Jianyun Zhao Shuang Liu Holly Edwards Kang Chen Hai Lin Jeffrey W Taub Yubin Ge Cancer Biology Graduate Program Wayne State University School of MedicineDetroitMichiganUSA National Engineering Laboratory for AIDS Vaccine School of Life SciencesJilin UniversityChangchunChina department of Pathology and Laboratory Medicine Weill Cornell MedicineNew YorkNew YorkUSA department of Pediatrics Wayne State University School of MedicineDetroitMichiganUSA department of oncology Wayne State University School of MedicineDetroitMichiganUSA Molecular Therapeutics Program Karmanos Cancer InstituteWayne State University School of MedicineDetroitMichiganUSA department of Obstetrics and Gynecology Wayne State University School of MedicineDetroitMichiganUSA Mucosal Immunology Studies Team National Institute of Allergy and Infectious DiseasesNational Institutes of HealthBethesdaMarylandUSA department of hematology and oncology The First Hospital of Jilin UniversityChangchunChina Division of Pediatric hematology and oncology Children’s Hospital of MichiganDetroitMichiganUSA.

Acute myeloid leukemia(AML)is a serious *** 5-year survival rates remain frustratingly low(65%for children and 26%for adults).Resistance to frontline chemotherapy(usually cytarabine)often develops;therefore a new treatment modality is ***-2 family proteins play an important role in balancing cell survival and *** antiapoptotic Bcl-2 family proteins have been found to be dysregulated in ***-199,a BH3 mimetic,was developed to target antiapoptotic protein *** ABT-199 has demonstrated promising results,resistance *** studies in AML show that ABT-199 alone decreases the association of proapoptotic protein Bim with Bcl-2,but this is compensated by increased association of Bim with prosurvival protein Mcl-1,stabilizing Mcl-1,resulting in resistance to *** this study,we investigated the antileukemic activity of the Mcl-1-selective inhibitor A-1210477 in combination with ABT-199 in AML *** found that A-1210477 synergistically induced apoptosis with ABT-199 in AML cell lines and primary patient *** synergistic induction of apoptosis was decreased upon Bak,Bax and Bim *** A-1210477 treatment alone also increased Mcl-1 protein levels,combination with ABT-199 reduced binding of Bim to *** results demonstrate that sequestration of Bim by Mcl-1,a mechanism of ABT-199 resistance,can be abrogated by combined treatment with the Mcl-1 inhibitor A-1201477.

关键词： chemotherapy alone treatment

Utility of an upright-type 11-gauge stereotactic vacuum-assisted biopsy device (Mammotome) for the diagnosis of breast microcalcifications

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The Chinese-German Journal of Clinical oncology 2009年第10期8卷 567-571页

作者： Ming Yang Takanori Ishida Motohiro Takeda Noriaki Ohuchi department of Breast Surgery the First Hospital of Jilin University Changchun 130021 China department of Surgical oncology Tohoku University School of Medicine Sendai Japan

Objective: The aim of this study was to evaluate the utility of an upright-type 11-gauge stereotactic vacuumassisted biopsy device (Mammotome) for the diagnosis of breast microcalcifications Methods: Between May 2001 and October 2005, 154 biopsies in 152 patients with microcalcifications were performed using the upright-type 11-gauge stereotactic vacuum-assisted biopsy device. Patients in whom this biopsy was diagnosed as carcinoma or a borderline lesion, had a subsequent surgical excision of the lesion. Histopathological and radiological features of the two specimens were then compared with each other. Results: Microcalcification was identified on specimen mammograms and microscopic slides in 97.4% of cases. Of 154 Mammotome biopsies 98 (63.6%) were benign, 51 (33.1%) were malignant, 3 (1.9%) showed atypical hyperplasia, and 2 (1.3%) were indeterminate, respectively. Of the 48 cases that received surgical excision, 6 of 36 ductal carcinomas in situ (16.7%) upstaged to invasive ductal carcinoma and 1 of 2 atypical ductal hyperplasias was upstaged to ductal carcinoma in situ. The positive predictive value of the 11-gauge Mammotome for the diagnosis of invasion in breast cancer was 100%. Linear calcification and pleomorphic calcification linear/segmental distribution was reliable indications of malignancy. The mean follow-up time of the benign lesions was 22 months, and without evidence of lesion growth. Complications included vasovagal reactions (6.3%), bleeding (0.6%) and hematoma (2.6%). Conclusion: The upright stereotactic 11-gauge Mammotome procedure is an effective and reliable method for the diagnosis of breast microcalcifications. It has minimal side effects. For lesions diagnosed as ADH or DCIS with the 11-gauge Mammotome, subsequent surgical excision should be performed.

关键词： stereotactic vacuum assistanted biopsy breast cancer mammography mammotome microcalcification

Mesentery solitary fibrous tumor with postoperative recurrence and sarcomatosis: A case report and review of literature

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Clinical oncology 2022年第4期13卷 303-313页

作者： Chong-Chi Chiu Haruaki Ishibashi Satoshi Wakama Yang Liu Yuan Hao Chao-Ming Hung Po-Huang Lee Kun-Ming Rau Hui-Ming Lee Yutaka Yonemura department of General Surgery E-Da Cancer HospitalKaohsiung 82445Taiwan School of Medicine College of MedicineIShou UniversityKaohsiung 82445Taiwan department of Medical Education and Research E-Da Cancer HospitalKaohsiung 82445Taiwan Peritoneal Surface Malignancy Center Kishiwada Tokushukai HospitalOsaka 596-8522Japan department of General Surgery Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghai 200025China department of General Surgery E-Da HospitalKaohsiung 82445Taiwan College of Medicine I-Shou UniversityKaohsiung 82445Taiwan department of hematology&oncology E-Da Cancer HospitalKaohsiung 82445Taiwan

BACKGROUND Solitary fibrous tumors are rare neoplasms of mesenchymal origin. They are often of low malignant potential and rarely metastasize. They frequently arise from the pleura and can occur at any soft tissue site in the body. However, these tumors rarely develop in the mesentery, peritoneal cavity or *** SUMMARY We report on a scarce case of solitary fibrous tumor of the rectal mesentery showing sarcomatosis about 4 years after previous tumor resection. This 69-yearold male had no clinical symptoms but was transferred to our hospital because of a suspected tumor recurrence from follow-up abdominal computed *** markers(CEA, CA 19-9 and CA 125) were within the normal range. Open laparotomy showed sarcomatosis, and pathology confirmed its mesenchymal origin and diagnosis as the solitary fibrous tumor. Our case may be the second recurrent mesentery solitary fibrous tumor reported to date, and the only one with progression to sarcomatosis. There has been no evidence of recurrence in follow-up at the 28 th mo after extensive intra-operative peritoneal lavage and cytoreductive *** Although there are few risk factors of cancer recurrence in this patient, careful long-term followup after cytoreductive surgery is necessary.

关键词： Solitary fibrous tumor of rectum mesentery Recurrence Sarcomatosis Extensive intra-operative peritoneal lavage Cytoreductive surgery Case report

International guideline on natural orifice specimen extraction surgery(NOSES)for colorectal cancer(2023 version)

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Holistic Integrative oncology 2023年第1期2卷 93-100页

作者： Zheng Liu Xu Guan Mingguang Zhang Xiyue Hu Ming Yang Junge Bai Jun Li Shaojun Yu Kefeng Ding Qingsi He Liang Kang Dan Ma Chuangang Fu Junhong Hu Ye Wei Donghui Sun Gang Yu Songbing He Changyou Wang Yanwei Gao Guiyu Wang Hongliang Yao Jian Peng Yangchun Zheng Bo Jiang Taiyuan Li Zhiguo Xiong Xuejun Sun Zhenning Wang William Meng William Tzu-Liang Chen Ming-Yin Shen John H.Marks Charles A.Ternent Darcy DShaw Jim SKhan Petr Tsarkov Inna Tulina Sergey Efetov Joaquim Manuel da Costa Pereira Fernanda Nogueira Ricardo Escalante Joel Leroy Avanish Saklani Audrius Dulskas Cuneyt Kayaalp Atsushi Nishimura Kay Uehara Woo-Yong Lee Sang-Hoo Kim Suk-Hwan Lee Xishan Wang Committee of Colorectal Cancer Society Chinese Anti-Cancer Association International NOSES Alliance department of Colorectal Surgery National Cancer CenterNational Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Science and Peking Union Medical CollegeBeijing 100021China department of Colorectal Surgery The Second Affiliated HospitalZhejiang University School of MedicineHangzhouChina department of General Surgery Shandong University Qilu HospitalJinanShandongChina department of Colorectal Surgery The Sixth Affiliated HospitalSun Yat-Sen UniversityGuangzhouChina department of General Surgery Xinqiao HospitalThird Military Medical UniversityChongqingChina department of Gastrointestinal Surgery Shanghai East HospitalTongji University School of MedicineShanghaiChina department of Anorectal Surgery First Affiliated HospitalZhengzhou UniversityZhengzhouHenanChina department of General Surgery Zhongshan HospitalFudan UniversityShanghaiChina department of Gastric and Colorectal Surgery Jilin University First HospitalChangchunChina department of General Surgery Qilu Hospital(Qingdao)Cheeloo College of MedicineShandong UniversityJinanChina department of General Surgery the First Affiliated Hospital of Soochow UniversitySuzhouJiangsuChina Affiliated hospital of North china university of Science and Technology TangshanHebeiChina Inner Mongolia Autonomous Region People’s hospital HuhhotInner Mongolia Autonomous RegionChina department of Colorectal Cancer Surgery the Second Affiliated Hospital of Harbin Medical UniversityHarbinHeilongjiangChina department of General Surgery The Second Xiangya HospitalCentral South UniversityChangshaHunanChina department of General Surgery Xiangya HospitalCentral South UniversityChangshaChina department of Gastrointestinal Surgery Sichuan Cancer HospitalChengduChina department of Colorectal and Anal Surgery Shanxi Cancer HospitalTaiyuanShanxiChina department of General Surgery The First Affiliated Hospital of Nanchang UniversityNanchangChina department of Gastrointestinal Surgery Hubei Provincial Cancer Hosp

Purpose In recent years,natural orifice specimen extraction surgery(NOSES)has gained widespread attention as an alternative *** the safety and feasibility of NOSES have been well documented,many questions remain open for *** aim of this guideline is to provide more evidence for the promotion of *** This guideline has been prepared by the CACA Committee of Colorectal Cancer Society and the International NOSES Alliance,based on the latest *** The guideline on NOSES for colorectal cancer include the definition,classification,technology requirement,indications,technical difficulties and clinical *** The guideline provides a full introduction of the theoretical and technical aspects of NOSES for colorectal cancer which will beneficial to development of NOSES.

关键词： Colorectal cancer Guideline Treatment Surgery Holistic integrative medicine Natural orifice specimen extraction surgery

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

四川生理科学杂志 2021年第1期43卷 158-158页

作者： Yi-Long Wu From the Guangdong Lung Cancer Institute Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences Guangzhou (Y.-L.W.) the Thoracic Surgery Department National Cancer Center–National Clinical Research Center for Cancer–Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing (J.H.) and the Lung Cancer Center Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai (S.L.) — all in China the department of Thoracic Surgery and oncology National Cancer Center Hospital East Kashiwa (M.T.) and the Department of Thoracic Oncology Kanagawa Cancer Center Yokohama (T.K.) — both in Japan the department of Medical oncology Austin Health Melbourne VIC Australia (T.J.) the department of Respiratory Diseases Evangelische Lungenklinik Berlin (C.G.) the department of Medical oncology Hospital de la Santa Creu i Sant Pau Barcelona (M.M.) and the Department of Oncology Hospital Universitario Fundación Jiménez Díaz Madrid (M.D.) the David Geffen School of Medicine at the university of California Los Angeles Los Angeles (J.W.G.) the Center of Innovative Technologies and oncology N.N. Blokhin Russian Cancer Center Russian Academy of Medical Sciences Moscow (K.L.) the department of oncology Asan Medical Center University of Ulsan College of Medicine (S.-W.K.) and the Precision Medicine Lung Cancer Center Konkuk University Medical Center (K.-Y.L.) — both in Seoul South Korea the department of Thoracic Surgery Cho Ray Hospital Ho Chi Minh City Vietnam (H.-V.V.) the Division of Medical oncology Faculty of Medicine Siriraj Hospital Bangkok Thailand (C.A.) the department of Internal Medicine National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan (C.-J.Y.) the Division of Thoracic oncology European Institute of Oncology IRCCS Milan (F.M.) and Medical Oncology 2 Istituto Oncologico Veneto IRCCS Padua (L.B.) — both in Italy the department of Medical oncology and hematology Univers

Background:Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor(EGFR)mutation-positive advanced non-small-cell lung cancer(NSCLC).The efficacy and safety of osimertinib as adjuvant therapy are ***:In this double-blind,phase 3 trial,we randomly assigned patients with completely resected EGFR mutation-positive NSCLC in a 1:1 ratio to receive either osimertinib(80 mg once daily)or placebo for 3 *** primary end point was disease-free survival among patients with stage Ⅱ to ⅢA disease(according to investigator assessment).

关键词： Lung NSCLC lung

帕博利珠单抗联合以铂类为基础的化疗治疗非小细胞肺癌合并稳定性脑转移患者的结局:KEYNOTE-021、-189和-407研究的汇总分析

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国肺癌杂志 2022年第1期25卷 I0007-I0018页

作者：周清(翻译校对) Steven F Powell Delvys Rodríguez-Abreu Corey J Langer Ali Tafreshi Luis Paz-Ares Hans-Georg Kopp Jeronimo Rodríguez-Cid Dariusz M Kowalski Ying Cheng Takayasu Kurata Mark M Awad Jinaxin Lin Bin Zhao M Catherine Pietanza Bilal Piperdi Marina C Garassino 广东省人民医院肺三科广东省医学科学院广东省肺癌研究所广州510080 Sanford Health Sioux FallsSouth Dakota Complejo hospitalario Universitario Insular-Materno Infantil Universidad de Las Palmas de Gran CanariaGran CanariaSpainospital Universitario Insular de Gran CanariaLas Palmas de Gran CanariaLas Palmas de Gran CanariaSpain Abramson Cancer Center University of PennsylvanialadelphiaPennsylvania Wollongong Private hospital University of WollongongWollongongAustralia hospital Universitario 12 de Octubre CNIOUniversidad Complutense and CiberoncMadridSpain Robert Bosch Centrum für Tumorerkrankungen Robert Bosch Cancer CenterKlinik SchillerhoheGerlingenGermany oncology Center Médica Sur Hospital-Instituto Nacional de Enfermedades RespiratoriasMexico CityMexico Maria Sklodowska-Curie National Research Institute of oncology WarsawPoland jilin Cancer hospital ChangchunJilinPeople's Republic of China department of Thoracic oncology Kansai Medical University HospitalHirakataOsakaJapan Massachusetts General hospital Cancer Center and Harvard Medical School BostonMassachusetts Merck Sharp&Dohme Corp. a subsidiary of Merck&Co.Inc.KenilworthNew Jersey Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori MilanItaly

背景与目的此项探索性分析回顾评价了晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的结局,旨在确定基线时合并脑转移是否会影响一线应用帕博利珠单抗联合化疗(pembrolizumab plus chemotherapy,PC)比对单用化疗的疗效。患... 详细信息

背景与目的此项探索性分析回顾评价了晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的结局,旨在确定基线时合并脑转移是否会影响一线应用帕博利珠单抗联合化疗(pembrolizumab plus chemotherapy,PC)比对单用化疗的疗效。患者和方法对KEYNOTE-021队列G(非鳞癌)、KEYNOTE-189(非鳞癌)和KEYNOTE-407(鳞癌)三项研究晚期NSCLC患者的数据进行汇总分析。患者接受含铂两药化疗和/或35个周期帕博利珠单抗治疗(每3周200 mg)。所有研究均纳入了经治或初治的稳定性脑转移患者(KEYNOTE-189与KEYNOTE-407研究纳入初治脑转移患者)。经治的脑转移患者已处于病情稳定的状态≥2周(KEYNOTE-021队列G患者≥4周),无新发或脑转移病灶扩大的证据且入组前至少3天以上未使用激素。初治的无症状脑转移患者需定期接受脑部影像学检查。结果共纳入1298例患者,其中171例有基线脑转移,1127例无脑转移。两组的中位随访时间(范围)在数据截止时分别为10.9(0.1-35.1)个月和11.0(0.1-34.9)个月。合并脑转移和无脑转移患者的总生存期[0.48(95%CI:0.32-0.70)和0.63(95%CI:0.53-0.75)]和无进展生存期[0.44(95%CI:0.31-0.62)和0.55(95%CI:0.48-0.63)]的风险比(PC/化疗)相似。合并脑转移的患者中,PC组和单用化疗组患者的中位总生存期分别为18.8个月和7.6个月,中位无进展生存期分别为6.9个月和4.1个月。无论是否合并脑转移,PC组患者的客观缓解率都高于单用化疗组,且缓解持续时间有显著延长。合并脑转移的患者中,PC组与单用化疗组的治疗相关不良事件发生率分别为88.2%和82.8%;而无脑转移的患者中,两组治疗相关不良事件的发生率分别为94.5%和90.6%。结论无论是否合并脑转移,与单用化疗相比,帕博利珠单抗联合以铂类为基础的组织学特异性化疗可改善所有PD-L1亚组的临床结局,其中包括PD-L1肿瘤比例评分<1%的患者,并且在晚期NSCLC患者中安全性良好。该方案是晚期NSCLC初治患者的标准方案,并可用于合并稳定性脑转移的患者。

关键词：帕博利珠单抗脑转移化疗非小细胞肺癌 PD-L1

Human genetic and immunological determinants of critical COVID-19 pneumonia

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

四川生理科学杂志 2021年第11期43卷 1947-1947页

作者： Qian Zhang St Giles Laboratory of Human Genetics of Infectious Diseases Rockefeller Branch The Rockefeller University New York NY USA Laboratory of Human Genetics of Infectious Diseases Necker Branch INSERM U1163 Necker Hospital for Sick Children Paris France university of Paris Imagine Institute Paris France Howard Hughes Medical Institute Paris France The Rockefeller university & Howard Hughes Medical Institute New York NY USA Necker hospital for Sick Children & INSERM Paris France department of Pediatrics Necker Hospital for Sick Children Paris France Cemil Taşcıoglu City hospital Istanbul Turkey Laboratory of Human Genetics of Infectious Diseases Necker Branch INSERM U1163 Necker Hospital for Sick Children Paris France Imagine Institute University of Paris Paris France Al Jalila Children’s hospital Dubai United Arab Emirates San Raffaele Telethon Institute for Gene Therapy IRCCS Ospedale San Raffaele and Vita Salute San Raffaele University Milan Italy Hospices Civils de Lyon Lyon France Helix San Mateo CA USA department of Intensive Care Medicine Critical Care Center CHU Lille Lille France Univ. Lille CNRS Inserm CHU Lille Institut Pasteur de Lille U1019-UMR9017-CIIL-Centre d’Infection et d’Immunité deLille Lille France Shupyk National Medical Academy for Postgraduate Education Kiev Ukraine department of Medical Microbiology University Medical Center Utrecht Utrecht The Netherlands Sidra Medicine Doha Qatar Primary Immunodeficiencies Group Department of Microbiology and Parasitology School of Medicine University of Antioquia Medellín Colombia School of Microbiology University of Antioquia Medellín Colombia IIBB-CSIC IDIBAPS Barcelona Spain department of Immunology Second Faculty of Medicine Charles University University Hospital in Motol Prague Czech Republic department of Immunology Dmitry Rogachev National Medical Research Center of Pediatric Hematology Oncology and Immunology Moscow Russia Pulmonology department Cliniques Universitaire

SARS-CoV-2 infection is benign in most individuals but,in-10%of cases,it triggers hypoxemic COVID-19 pneumonia,which becomes critical in-3%of *** ensuing risk of death(-1%)doubles every five years from childhood onward and is-1.5 times greater in men than in *** are the molecular and cellular determinants of critical COVID-19 pneumonia?Inborn errors of type I IFNs,including autosomal TLR3 and X-linked TLR7 deficiencies,are found in-1-5%of patients with critical pneumonia under 60 years old.

关键词： pneumonia critical cases